Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 19/20 | 0.41 |
| ▸ | SLC2A3 | P11169 | 19/20 | 0.41 |
| ▸ | SLC2A4 | P14672 | 19/20 | 0.41 |
| ▸ | SLC2A2 | P11168 | 8/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16503751 | 0.93 | EPAS1 (0.38) | SLC2A1SLC2A3SLC2A4SLC2A2EPAS1 | |
| SCHEMBL16503749 | 0.92 | EPAS1 (0.37) | SLC2A1SLC2A3SLC2A4SLC2A2EPAS1 | |
| SCHEMBL16503738 | 0.92 | EPAS1 (0.44) | SLC2A1SLC2A3SLC2A4SLC2A2EPAS1 | |
| SCHEMBL16503763 | 0.91 | EPAS1 (0.37) | SLC2A1SLC2A3SLC2A4SLC2A2EPAS1 | |
| SCHEMBL16572256 | 0.87 | EPAS1 (0.35) | SLC2A1SLC2A3SLC2A4SLC2A2EPAS1 | |
| SCHEMBL1696948 | 0.85 | EPAS1 (0.42) | EPAS1 | |
| SCHEMBL16503753 | 0.83 | EPAS1 (0.41) | EPAS1 | |
| SCHEMBL16503748 | 0.83 | EPAS1 (0.41) | EPAS1 | |
| SCHEMBL18828875 | 0.80 | EPAS1 (0.39) | SLC2A1SLC2A3SLC2A4SLC2A2EPAS1 | |
| SCHEMBL13085372 | 0.79 | SLC2A1 (0.39) | SLC2A1SLC2A3SLC2A4SLC2A2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980886-B2 | Anthranilic acid derivatives | BAYER CROPSCIENCE AG (DE) | 2015-03-17 | — | — | US | disclosed |
| US-8980886-B2 | Anthranilic acid derivatives | BAYER CROPSCIENCE AG (DE) | 2015-03-17 | — | — | US | disclosed |
| US-20110312953-A1 | ANTHRANILIC ACID DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312953-A1 | ANTHRANILIC ACID DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312953-A1 | ANTHRANILIC ACID DERIVATIVES | ANTXR2, NQO2, ACLY | SLC2A1 4190/4885SLC2A3 4342/4885SLC2A4 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.